Suzhou Basecare Medical Sets Out Board and Committee Structure

Suzhou Basecare Medical Corp. Ltd. Class H ( (HK:2170) ) has shared an announcement.

Suzhou Basecare Medical Corporation Limited has announced the composition of its board of directors, led by chairman and executive director Dr. Liang Bo, alongside two other executive directors, two non-executive directors and three independent non-executive directors. The company has also detailed the membership of its three key board committees—Audit Committee, Remuneration and Appraisal Committee, and Nomination Committee—with independent directors taking chair roles in the Audit and Remuneration and Appraisal Committees, and the chairman of the board leading the Nomination Committee, underscoring an emphasis on corporate governance, oversight and compliance for its stakeholders.

The most recent analyst rating on (HK:2170) stock is a Sell with a HK$2.00 price target. To see the full list of analyst forecasts on Suzhou Basecare Medical Corp. Ltd. Class H stock, see the HK:2170 Stock Forecast page.

More about Suzhou Basecare Medical Corp. Ltd. Class H

Suzhou Basecare Medical Corporation Limited is a Hong Kong-listed medical company based in Suzhou, China, operating in the healthcare and life sciences sector. It is governed by a board comprising executive, non-executive and independent non-executive directors, reflecting the typical corporate governance structure of a publicly traded biomedical or medtech firm serving domestic and potentially international markets.

Average Trading Volume: 123,581

Technical Sentiment Signal: Sell

Current Market Cap: HK$599M

For a thorough assessment of 2170 stock, go to TipRanks’ Stock Analysis page.